Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye dis... Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Mehr anzeigen
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...
PDUFA Date is April 2, 2025 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.61 | 12.8151260504 | 4.76 | 5.45 | 4.69 | 428403 | 5.10079427 | CS |
| 4 | 0.63 | 13.2911392405 | 4.74 | 5.45 | 4.09 | 579873 | 4.7699202 | CS |
| 12 | -0.35 | -6.11888111888 | 5.72 | 6.1695 | 4.09 | 474963 | 5.17563438 | CS |
| 26 | 1.54 | 40.2088772846 | 3.83 | 6.5476 | 3.1 | 480444 | 4.82004439 | CS |
| 52 | 2.19 | 68.8679245283 | 3.18 | 6.5476 | 2.71 | 583231 | 4.08049026 | CS |
| 156 | -1.52 | -22.06095791 | 6.89 | 11.97 | 1.42 | 912692 | 4.84587236 | CS |
| 260 | 0.23 | 4.47470817121 | 5.14 | 15.95 | 1.42 | 914810 | 6.78825282 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| ESGEiShares Inc iShares ESG Aware MSCI EM ETF | US$ 35,1115 (-0,39%) | 2,06M |
| LAESSEALSQ Corporation | US$ 1,24 (8,71%) | 1,57M |
| TLTiShares 20 plus Year Treasury Bond | US$ 92,1701 (-0,01%) | 962,9k |
| QQQInvesco QQQ Trust Series 1 | US$ 529,30 (-0,12%) | 865,92k |
| IGOViShares International Treasury Bond | US$ 39,761 (0,10%) | 844,93k |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
